Solifenacin succinate suspension 2.5 mg + Solifenacin succinate suspension 5 mg + Solifenacin succinate suspension 10 mg
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Urinary Bladder, Overactive
Conditions
Urinary Bladder, Overactive
Trial Timeline
Oct 20, 2010 → Aug 14, 2011
NCT ID
NCT01262391About Solifenacin succinate suspension 2.5 mg + Solifenacin succinate suspension 5 mg + Solifenacin succinate suspension 10 mg
Solifenacin succinate suspension 2.5 mg + Solifenacin succinate suspension 5 mg + Solifenacin succinate suspension 10 mg is a phase 1 stage product being developed by Astellas Pharma for Urinary Bladder, Overactive. The current trial status is completed. This product is registered under clinical trial identifier NCT01262391. Target conditions include Urinary Bladder, Overactive.
What happened to similar drugs?
20 of 20 similar drugs in Urinary Bladder, Overactive were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01262391 | Phase 1 | Completed |
Competing Products
20 competing products in Urinary Bladder, Overactive